FrancineMarieFossMD

Oncology • New Haven, CT

Cutaneous Lymphoma, Hematologic Oncology

Professor of Medicine, Yale University School of Medicine

Join to view full profile

Dr. Foss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Foss' full profile

Already have an account?

Office
800 Howard Ave
Yale Physicians Building
New Haven, CT 06519
Phone+1 203-785-7005

Fax+1 203-785-3788
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Brigham and Women's HospitalResidency, Internal Medicine, 1982 - 1985
University of Massachusetts Medical SchoolClass of 1982
National Institutes of Health Clinical CenterFellowship, Medical Oncology

Certifications & Licensure

MA State Medical License 1985 - 2025
CT State Medical License 2004 - 2024
MD State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Join now to see all

Clinical Trials

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Start of enrollment: 2005 Nov 09
Terminated
Phase 2
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Start of enrollment: 2004 Mar 14
Completed
Phase 2
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2001 May 01
Completed
Phase 4
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 2
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Start of enrollment: 2005 Oct 01
Completed
Phase 1
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Start of enrollment: 2006 Jul 01
Completed
Phase 2
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas Start of enrollment: 2009 Jan 01
Terminated
Phase 1, Phase 2
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Start of enrollment: 2010 Feb 01
Completed
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 1
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) Start of enrollment: 2012 Oct 01
Terminated
Phase 1
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
Active, not recruiting
Phase 2
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Start of enrollment: 2015 Jul 01
Active, not recruiting
Phase 1, Phase 2
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides Start of enrollment: 2019 Apr 02
Terminated
Phase 2
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma Start of enrollment: 2019 Jun 01
Withdrawn
Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Join now to see all

Publications & Presentations

PubMed

Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.
Goyal, A., Foss, F.> ;Expert Review of Anticancer Therapy. 2024 Feb 12
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy.
Ren, J., Liao, X., Lewis, J., Chang, J., Qu, R., Carlson, K., Foss, F., Girardi, M.> ;Nature Communications. 2024 Jan 15
2 citations
Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
Amrita Goyal, Daniel O'Leary, Francine Foss> ;Bone Marrow Transplantation. 2024 Jan 1
FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes.
Jonathan Avery, Sa Rang Kim, Wei Cheng, Francine Foss, Michael Girardi> ;JID Innovations. 2023 Sep 1
Clinicopathologic Features of Cutaneous T-Cell Lymphomas With Extracutaneous Metastasis: A Case Series.
Nana Matsumoto, Francine Foss, Mina Xu, Aadil Ahmed, Tang, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network.
Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H Advani, Stefano A Pileri, Martina Manni, Steven M Horwitz, Francine M Fo...> ;Blood Advances. 2023 Sep 12
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.
Emmilia Hodak, Larisa Geskin, Emmanuella Guenova, Pablo L Ortiz-Romero, Rein Willemze, Jie Zheng, Richard Cowan, Francine Foss, Cristina Mangas, Christiane Querfeld> ;American Journal of Clinical Dermatology. 2023 May 1
2 citations
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell L...
Julio C Chavez, Francine M Foss, Basem M William, Jonathan E Brammer, Sonali M Smith, Anca Prica, Jasmine M Zain, Joseph M Tuscano, Harsh Shah, Neha Mehta-Shah, Pravee...> ;Clinical Cancer Research. 2023 May 15
4 citations
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion.
Emmilia Hodak, Larisa Geskin, Emmanuella Guenova, Pablo L Ortiz-Romero, Rein Willemze, Jie Zheng, Richard Cowan, Francine Foss, Cristina Mangas, Christiane Querfeld> ;American Journal of Clinical Dermatology. 2023 Jan 1
9 citations
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
Mengyang Di, Iris Isufi, Lohith Gowda, Stuart E Seropian, Francine M Foss, Howard P Forman, Scott F Huntington, Potnis, K.> ;Blood Advances. 2023 Mar 14
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma.
Jonathan Avery, Namrata Chandhok, Chanelle Rainey, Richard Torres, Scott Huntington, Iris Isufi, Stuart Seropian, Mina L Xu, Francine Foss> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Sep 1
1 citations
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.
Nazila Shafagati, Min J Koh, Leora Boussi, Hyun J Park, Robert Stuver, Paul Bain, Francine M Foss, Changyu Shen, Salvia Jain> ;Blood Advances. 2022 Aug 23
5 citations
Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations.
Jingjing Ren, Rihao Qu, Nur-Taz Rahman, Julia M Lewis, Amber Loren Ong King, Xiaofeng Liao, Fatima N Mirza, Kacie R Carlson, Yaqing Huang, Scott Gigante, Benjamin Evan...> ;Blood Advances. 2023 Feb 14
1 citations
Safety considerations with the current treatments for peripheral T-cell lymphoma.
Tarsheen Sethi, Francesca Montanari, Francine Foss> ;Expert Opinion on Drug Safety. 2022 May 1
3 citations
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow...
Hemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B Alkhateeb, Susan Bal, Mohamed A Kharfan-Dabaja, Bhagirathbhai Dholaria, Francine Foss, Lohith Gowda, Deepa...> ;Transplantation and Cellular Therapy. 2022 Apr 1
45 citations
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
Elise A. Olsen, Sean Whittaker, Rein Willemze, Lauren C. Pinter-Brown, Francine M. Foss, Larisa J. Geskin, Lawrence H. Schwartz, Steven M. Horwitz, Joan Guitart, John ...> ;Blood. 2021 Nov 10
2 citations
Adverse cardiovascular events in patients treated with mogamulizumab.
Mariana L Henry, Kirstin Cook, Jennifer M Kwan, Angela Higgins, Jason Cuomo, Francine Foss, Lauren A Baldassarre> ;American Heart Journal Plus. 2021 Sep 1
Uncovering the Potential of Phosphatidylinositol 3-Kinase Inhibitors in Cutaneous T-Cell Lymphoma: Insights from High-Throughput In Vitro Screenings.
A.O. King, Fatima N. Mirza, Julia M. Lewis, Shiela Umlauf, Yulia V. Surovtseva, Kacie R. Carlson, Francine M. Foss, Michael Girardi> ;The Journal of Investigative Dermatology. 2021 Jul 19
15 citations
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial
Richard A Cowan, Julia Scarisbrick, P. L. Zinzani, Jan P. Nicolay, Lubomir Sokol, Lauren C. Pinter-Brown, Pietro Quaglino, Lars Iversen, Reinhard Dummer, Amy Musiek, F...> ;Journal of the European Academy of Dermatology and Venereology. 2021 Jul 17
2 citations
Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma.
Jennifer M. Kwan, Natalija Odanovic, Amit Arbune, Angela Y. Higgins, Mariana L. Henry, Daniel Greif, Francine M. Foss, Lauren A. Baldassarre> ;JACC. Case Reports. 2021 Jul 7
7 citations
How we treat advanced stage cutaneous T-cell lymphoma – mycosis fungoides and Sézary syndrome
Tarsheen K. Sethi, Francesca Montanari, Francine M. Foss, Nishitha Reddy> ;British Journal of Haematology. 2021 May 14
Necrotic papulonodules on the legs.
Amanda Zhou, William Damsky, Michael Girardi, Francine M. Foss, Matthew D. Vesely> ;JAAD Case Reports. 2021 Mar 13
9 citations
Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion.
Sarah Perreault, Molly Schiffer, Virginia Clinchy-Jarmoszko, Nicole Bocchetta, Lisa Barbarotta, Osama Abdelghany, Francine M. Foss, Scott F. Huntington, Stuart Seropia...> ;American Journal of Health-System Pharmacy. 2021 Jun 7
27 citations
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral ...
Patrick B. Johnston, Amanda F. Cashen, Petros Nikolinakos, Anne W. Beaven, Stefan K. Barta, Gajanan Bhat, Steven J. Hasal, Sven de Vos, Yasuhiro Oki, Changchun Deng, F...> ;Experimental Hematology & Oncology. 2021 Feb 18
3 citations
New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
Suzanne Xu, Francine M. Foss> ;Expert Review of Anticancer Therapy. 2021 Feb 7
Join now to see all

Journal Articles

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer

Abstracts/Posters

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Emerging Role of Novel Therapies in Cutaneous T-Cell Lymphoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Diagnosis & Treatment of Pregnancy-Related Cancers in Women: Pregnancy, Fertility & Beyond
Yale CME, New Haven, Connecticut - 6/8/2012
Join now to see all

Authored Content

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic MalignanciesFebruary 4th, 2020
T-cell Lymphoma Registries: What Have We Learned?September 11th, 2019

Grant Support

Intravenous Bcx34 In Refractory T Cell &Non-T Cell MalignanciesNational Center For Research Resources2000–2002
IL2 With Photopheresis For Cutaneous T Cell LymphomaNational Center For Research Resources2000–2002
Docetaxel &Trastuzumab In HER2 Expressing Metastatic Breast CancerNational Center For Research Resources2000–2002
Cordycepin + Deoxycoformycin In Refractory Td-T-Positive LeukemiaNational Center For Research Resources2000–2002
94010 Phase I Study Of Oral BCX 34 In Patients With T Cell MalignanciesNational Center For Research Resources1999–2000
Biology And Signal Transduction Of The IL-7 Receptor ProgramNational Cancer Institute1998–2000
Biology And Signal Transduction Of The IL-7 Receptor ProgramNational Cancer Institute1996–1997